SIGA TECHNOLOGIES INC. - COMMON STOCK

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

06 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

08 Aug 2023 15:05:02 By Nasdaq GlobeNewswire

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

27 Jul 2023 15:45:00 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

27 Jul 2023 06:30:00 By Nasdaq GlobeNewswire

SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

27 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three Months Ended March 31, 2023

04 May 2023 15:05:01 By Nasdaq GlobeNewswire

SIGA Declares Special Cash Dividend of $0.45 Per Share

04 May 2023 06:30:00 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results

27 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022

02 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

17 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022

03 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

27 Oct 2022 15:15:00 By Nasdaq GlobeNewswire

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

12 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®

29 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)

26 Sep 2022 09:07:14 By Nasdaq GlobeNewswire

SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®

09 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022

04 Aug 2022 15:05:07 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results

28 Jul 2022 15:15:00 By Nasdaq GlobeNewswire